Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease

  • Ashley V. Geerlinks
  • Thomas G. Gross
  • Angela S. PunnettEmail author


Post-transplantation lymphoproliferative disorders (PTLD) describe a spectrum of pathologic and clinical entities that may develop in the setting of decreased T-cell function and altered immune surveillance following haematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT). Increasing knowledge of risk factors, including the pivotal role of EBV, has led to some successful pre-emptive practices and a decreased incidence of early disease. However, PTLD remains a significant cause of morbidity and mortality following paediatric transplant and significant contributor to the paediatric non-Hodgkin lymphoma (NHL) burden. Treatment strategies for PTLD must be tailored to the individual patient context with input from the interdisciplinary team. An improved understanding of the molecular pathobiology of the disease and the complex interplay of host, EBV and tumour is necessary to better define high-risk groups, refine pathological diagnosis and plan management. Prevention of disease remains the ultimate goal.


Post-transplant lymphoproliferative disease PTLD Solid organ transplantation Haematopoietic stem cell transplantation EBV NHL 


  1. 1.
    Akbas A, Tiede C, Lemound J, Maecker-Kolhoff B, Kreipe H, Hussein K. Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation. Transpl Int. 2015;28:1299–307.PubMedCrossRefGoogle Scholar
  2. 2.
    AlDabbagh MA, Gitman MR, Kumar D, Humar A, Rotstein C, Husain S. The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated Posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review. Am J Transplant. 2017;17:770–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Allen UD, Farkas G, Hebert D, Weitzman S, Stephens D, Petric M, Tellier R, Ngan B, Fecteau A, West L, Wasfy S. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant. 2005;9:450–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Allen U, Diane H, Dorothy M, Yigal D, Samia W. Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988–97: a Canadian multi-centre experience. Pediatr Transplant. 2001;5:198–203.PubMedCrossRefGoogle Scholar
  5. 5.
    Aull MJ, Buell JF, Jennifer T, Roy First M, Alloway RR, Hanaway MJ, Wagoner L, Gross TG, Beebe T, Steve Woodle E. Experience with 274 cardiac Transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation. 2004;78:1676–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Babel N, Vergopoulos A, Trappe RU, Oertel S, Hammer MH, Karaivanov S, Schneider N, Riess H, Papp-Vary M, Neuhaus R, Gondek LP, Volk HD, Reinke P. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation. 2007;84:387–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Bahmanyar M, Shakibazad N, Imanieh MH, Dehghani SM. Soft palate ulcer: an unusual presentation of a posttransplant lymphoproliferative disorder. J Pediatr Hematol Oncol. 2017;39:e97–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Bakker NA, Pruim J, de Graaf W, van Son WJ, van der Jagt EJ, van Imhoff GW. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant. 2006;6:1984–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation. 2007;83:433–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, Prockop SE, Koehne G, O’Reilly RJ. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood. 2010;116:5045–9.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Bata BM, Pulido JS, Patel SV, Khan SP, Salomao D, Boyce TG, Bothun ED. Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma–type morphology after heart transplant. J Am Assoc Pediatr Ophthalmol Strabismus {JAAPOS}. 2018;22:159–61.CrossRefGoogle Scholar
  12. 12.
    Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P, Garnier JL, Le Bidois J, Le Deist F, Blanche S, Fischer A. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood. 1998;92:3137–47.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M, Wadowsky RM, Rowe DT, Webber SA. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant. 2008;8:442–5.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Blanche S, Le Deist F, Veber F, Lenoir G, Fischer AM, Brochier J, Boucheix C, Delaage M, Griscelli C, Fischer A. Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies: two cases after HLA-mismatched bone marrow transplantation. Ann Intern Med. 1988;108:199–203.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Bocian J, Januszkiewicz-Lewandowska D. Utility of quantitative EBV DNA measurements in cerebrospinal fluid for diagnosis and monitoring of treatment of central nervous system EBV-associated post-transplant lymphoproliferative disorder after allogenic hematopoietic stem cell transplantation. Ann Transplant. 2014;19:253–6.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012;9:510–9.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Bollard CM, Stephen G, Helen Huls M, Leen AM, Gee AP, Rooney CM. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein–Barr virus-associated lymphoma. Cytotherapy. 2011;13:518–22.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Bonney DK, Htwe EE, Turner A, Kelsey A, Shabani A, Hughes S, Hughes I, Wynn RF. Sustained response to intrathecal rituximab in EBV associated post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer. 2012;58:459–61.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Bordon V, Padalko E, Benoit Y, Dhooge C, Laureys G. Incidence, kinetics, and risk factors of Epstein–Barr virus viremia in pediatric patients after allogeneic stem cell transplantation. Pediatr Transplant. 2012;16:144–50.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Buell JF, Gross TG, Hanaway MJ, Trofe J, Roy-Chaudhury P, First MR, Woodle ES. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005;37:954–5.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Cavaliere R, Petroni G, Lopes MB, Schiff D. Primary central nervous system post-transplantation lymphoproliferative disorder. Cancer. 2010;116:863–70.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Ceppi F, Weitzman S, Woessmann W, Davies K, Lassaletta A, Reismuller B, Mellgren K, Uyttebroeck A, Maia I, Abdullah S, Miakova N, Glaser D, Cohn R, Abla O, Attarbaschi A, Alexander S. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: an international retrospective study. Am J Hematol. 2016;91:486–91.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T. Prospective Epstein–Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment. Transpl Infect Dis. 2016;18:44–54.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Chinnock R, Webber SA, Dipchand AI, Brown RN, George JF, Transplant SPH. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients. Am J Transplant. 2012;12:3061–8.CrossRefGoogle Scholar
  25. 25.
    Chiou FK, Beath SV, Wilkie GM, Vickers MA, Morland B, Gupte GL. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children. Pediatr Transplant. 2018;22(2), e13133.CrossRefGoogle Scholar
  26. 26.
    Choquet S, Varnous S, Deback C, Golmard JL, Leblond V. Adapted treatment of Epstein–Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation. Am J Transplant. 2014;14:857–66.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S. ‘CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. haematologica. 2007;92:273–4.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, Furione M, Maccario R, Locatelli F. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7:1648–55.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M, Vigano M, Fiocchi R, Rossi G, Ginevri F, Gridelli B, Moretta A, Montagna D, Locatelli F, Gerna G, Maccario R. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592–8.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Comoli P, Maccario R, Locatelli F, Valente U, Basso S, Garaventa A, Tomà P, Botti G, Melioli G, Baldanti F. Treatment of EBV-related post-renal Transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant. 2005;5:1415–22.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Czyzewski K, Styczynski J, Krenska A, Debski R, Zajac-Spychala O, Wachowiak J, Wysocki M. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2013;54:503–6.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the north American pediatric renal Transplant cooperative Study. Pediatr Transplant. 2002;6:396–9.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant. 2012;12:976–83.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Dharnidharka VR, Martz KL, Stablein DM, Benfield MR. Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. Am J Transplant. 2011;11:751–8.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood. 2015;126:2274–83.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Dotti G, Fiocchi R, Motta T, Mammana C, Gotti E, Riva S, Cornelli P, Gridelli B, Viero P, Oldani E, Ferrazzi P, Remuzzi G, Barbui T, Rambaldi A. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation. 2002;74:1095–102.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, Boulad F, Castro-Malaspina H, George D, Jakubowski A, Koehne G, Papadopoulos EB, Scaradavou A, Small TN, Khalaf R, Young JW, O’Reilly RJ. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119:2644–56.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Dror Y, Greenberg M, Taylor G, Superina R, Hebert D, West L, Connolly B, Sena L, Allen U, Weitzman S. Lymphoproliferative disorders after organ transplantation in children. Transplantation. 1999;67:990–8.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Dulek DE, Michaels MG. Into thin air: predicting PTLD in pediatric lung transplant patients. Pediatr Transplant. 2017;21(6), e13029.CrossRefGoogle Scholar
  41. 41.
    Dumas PY, Ruggeri A, Robin M, Crotta A, Abraham J, Forcade E, Bay JO, Michallet M, Bertrand Y, Socié G. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Societe Francaise de Greffe de Moelle-Therapie Cellulaire collaborative study. Bone Marrow Transplant. 2013;48:253.PubMedCrossRefGoogle Scholar
  42. 42.
    Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, Tsai DE. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6:569–76.PubMedCrossRefGoogle Scholar
  43. 43.
    Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–901.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Engels EA, Savoldo B, Pfeiffer RM, Costello R, Zingone A, Heslop HE, Landgren O. Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation. 2013;95:519–26.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Evens AM, Choquet S, Kroll-Desrosiers AR, Jagadeesh D, Smith SM, Morschhauser F, Leblond V, Roy R, Barton B, Gordon LI, Gandhi MK, Dierickx D, Schiff D, Habermann TM, Trappe R. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the Modern Era. Am J Transplant. 2013: n/a-n/aGoogle Scholar
  46. 46.
    Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet. 1998;352:1285.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Ferreiro JF, Morscio J, Dierickx D, Vandenberghe P, Gheysens O, Verhoef G, Zamani M, Tousseyn T, Wlodarska I. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. Am J Transplant. 2016;16:414–25.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Francis A, Johnson DW, Craig JC, Wong G. Incidence and predictors of Cancer following kidney transplantation in childhood. Am J Transplant. 2017;17:2650–8.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Fryer JF, Heath AB, Wilkinson DE, Minor PD, Group Collaborative Study. A collaborative study to establish the 1st WHO international standard for Epstein-Barr virus for nucleic acid amplification techniques. Biologicals. 2016;44:423–33.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Fukushima D, Sato K, Kawagishi N, Ohuchi N, Satomi S. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. Transplantation. 2015;99:114–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Gajarski RJ, Blume ED, Urschel S, Schechtman K, Zheng J, West LJ, Altamirano L, Miyamoto S, Naftel DC, Kirklin JK, Zamberlan MC, Canter CE, Study IPHT. Infection and malignancy after pediatric heart transplantation: the role of induction therapy. J Heart Lung Transplant. 2011;30:299–308.PubMedCrossRefGoogle Scholar
  52. 52.
    Gallot G, Vollant S, Saïagh S, Clémenceau B, Vivien R, Cerato E, Bignon J-D, Ferrand C, Jaccard A, Vigouroux S. T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study. J Immunother. 2014;37:170–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Gandhi MK, Wilkie GM, Dua U, Mollee PN, Grimmett K, Williams T, Whitaker N, Gill D, Crawford DH. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant. 2007;7:1293–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Gheorghe G, Radu O, Milanovich S, Hamilton RL, Jaffe R, Southern JF, Ozolek JA. Pathology of central nervous system posttransplant lymphoproliferative disorders: lessons from pediatric autopsies. Pediatr Dev Pathol. 2013;16:67–73.PubMedCrossRefGoogle Scholar
  55. 55.
    Ginat DT, Purakal A, Pytel P. Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma. J Neuro-Oncol. 2015;125:297–305.CrossRefGoogle Scholar
  56. 56.
    Glotz D, Chapman JR, Dharnidharka VR, Hanto DW, Castro MC, Hirsch HH, Leblond V, Mehta AK, Moulin B, Pagliuca A, Pascual J, Rickinson AB, Russo FP, Trappe RU, Webster AC, Zuckermann AO, Gross TG. The Seville expert workshop for progress in posttransplant lymphoproliferative disorders. Transplantation. 2012;94:784–93.PubMedCrossRefGoogle Scholar
  57. 57.
    Green M, Bueno J, Rowe D, Mazariegos G, Qu L, Abu-Almagd K, Reyes J. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation. 2000;70:593–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Green M, Michaels MG, Katz BZ, Burroughs M, Gerber D, Shneider BL, Newell K, Rowe D, Reyes J. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant. 2006;6:1906–12.PubMedCrossRefGoogle Scholar
  59. 59.
    Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant. 2009;13:319–23.PubMedCrossRefGoogle Scholar
  60. 60.
    Green, Michael, and Marian Michaels. 2010. Prevention of Epstein—Barr virus infection and posttransplant lymphoproliferative disease following transplantation. In: Post-transplant lymphoproliferative disorders, Berlin, Heidelberg: Springer.CrossRefGoogle Scholar
  61. 61.
    Grinyo J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90:1521–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol. 2005;23:6481–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, Smith LM, Hayashi RJ. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children’s Oncology Group report. Am J Transplant. 2012;12:3069–75.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK, Wagner JE, Filipovich AH. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 1999;23:251–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Gupta S, Fricker FJ, Gonzalez-Peralta RP, Slayton WB, Schuler PM, Dharnidharka VR. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr Transplant. 2010;14:896–902.PubMedCrossRefGoogle Scholar
  66. 66.
    Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013;119:2300–8.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Haque T, Chaggar T, Schafers J, Atkinson C, McAulay KA, Crawford DH. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol. 2011;83:311–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123–31.PubMedCrossRefGoogle Scholar
  69. 69.
    Harjunpää A, Wiklund T, Collan J, Janes R, Rosenberg J, Lee D, Grillo-López A, Meri S. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma. 2001;42:731–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Hart M, Thakral B, Yohe S, Balfour HH Jr, Singh C, Spears M, McKenna RW. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder. Am J Surg Pathol. 2014;38:1522–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Hayashi RJ, Kraus MD, Patel AL, Canter C, Cohen AH, Hmiel P, Howard T, Huddleston C, Lowell JA, Mallory G, Mendeloff E, Molleston J, Sweet S, DeBaun MR. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol. 2001;23:14–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Hayes D Jr, Breuer CK, Horwitz EM, Yates AR, Tobias JD, Shinoka T. Influence of Posttransplant lymphoproliferative disorder on survival in children after heart transplantation. Pediatr Cardiol. 2015;36:1748–53.PubMedCrossRefGoogle Scholar
  73. 73.
    Haynes SE, Saini S, Schowengerdt KO. Post-transplant lymphoproliferative disease and other malignancies after pediatric cardiac transplantation: an evolving landscape. Curr Opin Organ Transplant. 2015;20:562–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Henry DD, Hunger SP, Braylan RC, Dharnidharka VR. Low viral load post-transplant lymphoproliferative disease localized within the tongue. Transpl Infect Dis. 2008;10:426–30.PubMedCrossRefGoogle Scholar
  75. 75.
    Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331:679–80.PubMedCrossRefGoogle Scholar
  76. 76.
    Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–35.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Hinrichs C, Wendland S, Zimmermann H, Eurich D, Neuhaus R, Schlattmann P, Babel N, Riess H, Gartner B, Anagnostopoulos I, Reinke P, Trappe RU. IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transpl Int. 2011;24:892–903.PubMedCrossRefGoogle Scholar
  78. 78.
    Hocker B, Fickenscher H, Delecluse HJ, Bohm S, Kusters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schroder M, Billing H, Fichtner A, Feneberg R, Sander A, Kopf-Shakib S, Susal C, Tonshoff B. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis. 2013;56:84–92.PubMedCrossRefGoogle Scholar
  79. 79.
    Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262–74.PubMedCrossRefGoogle Scholar
  80. 80.
    Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, Greil J, Albert MH, Schwinger W, Nathrath M. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1–specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol. 2012;31:39–48.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Iu LP, Yeung JC, Loong F, Chiang AK. Successful treatment of intraocular post-transplant lymphoproliferative disorder with intravenous rituximab. Pediatr Blood Cancer. 2015;62:169–72.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Kamani NR, Kumar S, Hassebroek A, Eapen M, LeRademacher J, Casper J, Cowan M, Sanchez de Toledo J, Ferster A, Szabolcs P, Wingard JR, Horwitz E, Filipovich AH. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2011;17:1783–9.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Kanakry JA, Kasamon YL, Bolanos-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, Ghosh N, Gladstone DE, Gocke CD, Huff CA, Kanakry CG, Luznik L, Matsui W, Mogri HJ, Swinnen LJ, Symons HJ, Jones RJ, Ambinder RF. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013;19:1514–7.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77:299–311.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Kelly DA, Bucuvalas JC, Alonso EM, Karpen SJ, Allen U, Green M, Farmer D, Shemesh E, McDonald RA. Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:798–825.PubMedCrossRefGoogle Scholar
  86. 86.
    Kerkar N, Morotti RA, Madan RP, Shneider B, Herold BC, Dugan C, Miloh T, Karabicak I, Strauchen JA, Emre S. The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant. 2010;14:504–11.PubMedCrossRefGoogle Scholar
  87. 87.
    Kinch A, Sundstrom C, Tufveson G, Glimelius I. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2016;57:2351–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ, Potdar S, Shapiro R, Dharnidharka VR, Kauffman HM. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619–25.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Koo J, Dawson DW, Dry S, French SW, Naini BV, Wang HL. Allograft biopsy findings in patients with small bowel transplantation. Clin Transpl. 2016;30:1433–9.CrossRefGoogle Scholar
  90. 90.
    Krasuska-Sławińska E, Izabela M-C, Pawłowska J, Dembowska-Bagińska B, Pronicki M, Olczak-Kowalczyk D. Post-Transplant lymphoproliferative disorder (PTLD) manifesting in the Oral cavity of a 13-year-old liver Transplant recipient (LTx). Ann Transplant. 2015;20:478–82.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    L’huillier AG, Dipchand A, Ng V, Hebert D, Avitzur Y, Solomon M, Yeung S, Allen UD. Post-transplant lymphoproliferative disorder in pediatric patients: Clinical sites of occurrence and related survival rates. In: In Open Forum Infectious Diseases, 2342. Oxford University: Press; 2016.Google Scholar
  92. 92.
    Laberko A, Bogoyavlenskaya A, Shelikhova L, Shekhovtsova Z, Balashov D, Voronin K, Kurnikova E, Boyakova E, Raykina E, Brilliantova V, Pirumova V, Novichkova G, Maschan A, Maschan M. Risk factors for and the Clinical impact of cytomegalovirus and Epstein-Barr virus infections in pediatric recipients of TCR-alpha/beta- and CD19-depleted grafts. Biol Blood Marrow Transplant. 2017;23:483–90.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Lake W, Chang JE, Kennedy T, Morgan A, Salamat S, Baskaya MK. A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics. Neurosurgery. 2013;72:960–70. discussion 70PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Lazda VA. Evaluation of Epstein-Barr virus (EBV) antibody screening of organ donors for allocation of organs to EBV serostatus matched recipients. Transplant Proc. 2006;38:3404–5.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Leblond V, Dhedin N, Bruneel M-FM, Choquet S, Hermine O, Porcher R, Quoc SN, Davi F, Charlotte F, Dorent R. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001;19:772–8.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transpl. 2006;20:389–93.CrossRefGoogle Scholar
  98. 98.
    Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O’Mahony CA, Goss JA. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005;5:2222–8.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Lieberman F, Yazbeck V, Raptis A, Felgar R, Boyiadzis M. Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. J Neuro-Oncol. 2012;107:225–32.CrossRefGoogle Scholar
  100. 100.
    Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, Porter DL, Vonderheide RH, Bagg A, Heitjan DF. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant. 2015;15:2665–73.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, Hoyer P, Koepf S, Kraemer U, Laube GF, Muller-Wiefel DE, Netz H, Pohl M, Toenshoff B, Wagner HJ, Wallot M, Welte K, Melter M, Offner G, Klein C. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol. 2007;25:4902–8.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Maecker-Kolhoff B, Beier R, Zimmermann M, Schlegelberger B, Baumann U, Mueller C, Pape L, Reiter A, Rossig C, Schubert S, Toenshoff B, Wingen A, Meissner B, Kebelmann-Betzing C, Henze G, Kreipe HH, Klein C. Response-adapted sequential Immuno-chemotherapy of post-Transplant lymphoproliferative disorders in pediatric solid Organ Transplant recipients: results from the prospective Ped-PTLD 2005 trial. Blood. 2014;124:4468.Google Scholar
  103. 103.
    Marks WH, Ilsley JN, Dharnidharka VR. Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. Transplant Proc. 2011;43:1395–404.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    McAulay KA, Haque T, Crawford DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer. 2009;101:1019–27.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martin MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998;66:1604–11.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Messahel B, Taj MM, Hobson R, Hadzic N, Ramsay A, Hann I, Pinkerton R. Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children’s Cancer Study Group (UKCCSG) retrospective review. Leuk Lymphoma. 2006;47:2584–9.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O’connor OA. Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. Br J Haematol. 2015;171:491–500.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalšek D, Jaeger G, Ledderose G. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115:2960–70.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Morscio J, Dierickx D, Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol. 2013;2013:150835.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Mynarek M, Schober T, Behrends U, Maecker-Kolhoff B. Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. Clin Dev Immunol. 2013;2013:814973.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W, Group Studies of Pediatric Liver Transplantation Research. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. Liver Transpl. 2013;19:730–40.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Nassif S, Kaufman S, Vahdat S, Yazigi N, Kallakury B, Island E, Ozdemirli M. Clinicopathologic features of post-transplant lymphoproliferative disorders arising after pediatric small bowel transplant. Pediatr Transplant. 2013;17:765–73.PubMedCrossRefGoogle Scholar
  113. 113.
    Nee R, Hurst FP, Dharnidharka VR, Jindal RM, Agodoa LY, Abbott KC. Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation. Transplantation. 2011;92:190–5.PubMedCrossRefGoogle Scholar
  114. 114.
    Opelz G, Daniel V, Naujokat C, Fickenscher H, Döhler B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol. 2007;8:212–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Opelz G, Döhler B. Lymphomas after solid Organ Transplantation: a collaborative Transplant Study report. Am J Transplant. 2004;4:222–30.PubMedCrossRefGoogle Scholar
  116. 116.
    Orjuela MA, Alobeid B, Liu X, Siebert AL, Kott ER, Addonizio LJ, Morris E, Garvin JH, Lobritto SJ, Cairo MS. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. Br J Haematol. 2011;152:733–42.PubMedCrossRefGoogle Scholar
  117. 117.
    Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–91.CrossRefGoogle Scholar
  118. 118.
    Parker A, Kristin B, Andrew Bradley J, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients–BCSH and BTS Guidelines. Br J Haematol. 2010;149:675–92.PubMedCrossRefGoogle Scholar
  119. 119.
    Parrish A, Fenchel M, Storch GA, Buller R, Mason S, Williams N, Ikle D, Conrad C, Faro A, Goldfarb S, Hayes D Jr, Melicoff-Portillo E, Schecter M, Visner G, Sweet S, Danziger-Isakov L, Children Clinical Trials in Organ Transplantation in. Epstein-Barr viral loads do not predict post-transplant lymphoproliferative disorder in pediatric lung transplant recipients: a multicenter prospective cohort study. Pediatr Transplant. 2017;21:e13011.CrossRefGoogle Scholar
  120. 120.
    Perrine SP, Hermine O, Small T, Suarez F, O’Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109:2571–8.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett. 2015;369:37–44.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Picarsic J, Jaffe R, Mazariegos G, Webber SA, Ellis D, Green MD, Reyes-Mugica M. Post-transplant Burkitt lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder. Cancer. 2011;117:4540–50.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Posfay-Barbe KM, Siegrist C-A. Immunization and transplantation–what is new and what is coming? Pediatr Transplant. 2009;13:404–10.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol. 2011;86:206–9.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Ramos E, Hernandez F, Andres A, Martinez-Ojinaga E, Molina M, Sarria J, Lopez-Santamaria M, Prieto G. Post-transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation: incidence, clinical features and outcome. Pediatr Transplant. 2013;17:472–8.CrossRefGoogle Scholar
  126. 126.
    Reshef R, Luskin MR, Kamoun M, Vardhanabhuti S, Tomaszewski JE, Stadtmauer EA, Porter DL, Heitjan DF, E. Tsai de. Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant. 2011a;11:817–25.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, Krok KL, Goldberg LR, Porter DL, Stadtmauer EA, Tsai DE. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder( bigstar). Am J Transplant. 2011b;11:336–47.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Riebel T, Kebelmann-Betzing C, Scheer I. Ultrasound in abdominal and soft-tissue childhood PTLD (post-transplant lymphoproliferative disease). Ultraschall Med. 2007;28:201–5.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Rodriguez L, Punnett A. Posttransplant lymphoproliferative disorders following solid organ transplantation. In: Dr. Randhawa G, editor. Organ donation and transplantation – public policy and clinical perspectives. 2012. ISBN: 978-953-51-0039-3, InTech. Available from: Scholar
  130. 130.
    Rooney CM, Ng CYC, Loftin S, Smith CA, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9–13.PubMedCrossRefGoogle Scholar
  131. 131.
    Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549–55.PubMedGoogle Scholar
  132. 132.
    Rouce RH, Louis CU, Heslop HE. EBV lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014;21:476.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein–Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis. 2000;3:79–87.CrossRefGoogle Scholar
  134. 134.
    Ruf S, Behnke-Hall K, Gruhn B, Reiter A, Wagner HJ. EBV load in whole blood correlates with LMP2 gene expression after pediatric heart transplantation or allogeneic hematopoietic stem cell transplantation. Transplantation. 2014;97:958–64.PubMedCrossRefGoogle Scholar
  135. 135.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation. 2012;93:73–81.PubMedCrossRefGoogle Scholar
  136. 136.
    Saueressig MG, Boussaud V, Amrein C, Guillemain R, Souilamas J, Souilamas R. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transpl. 2011;25:E430–6.CrossRefGoogle Scholar
  137. 137.
    Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942–9.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Schachtner T, Reinke P. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study. Transpl Infect Dis. 2016;18:881–8.PubMedCrossRefGoogle Scholar
  139. 139.
    Schiffer L, Henke-Gendo C, Wilsdorf N, Hussein K, Pape L, Schmitt C, Haller H, Schiffer M, Klein C, Kreipe H, Maecker-Kolhoff B. CXCL13 as a novel marker for diagnosis and disease monitoring in pediatric PTLD. Am J Transplant. 2012;12:1610–7.PubMedCrossRefGoogle Scholar
  140. 140.
    Schober T, Framke T, Kreipe H, Schulz TF, Grosshennig A, Hussein K, Baumann U, Pape L, Schubert S, Wingen AM, Jack T, Koch A, Klein C, Maecker-Kolhoff B. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation. 2013;95:240–6.PubMedCrossRefGoogle Scholar
  141. 141.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant. 2008;27:100–5.PubMedCrossRefGoogle Scholar
  142. 142.
    Selvaggi G, Sarkar S, Mittal N, Acar BC, Weppler D, Kato T, Tryphonopoulos P, Tzakis A, Ruiz P. Etiology and management of alimentary tract ulcers in pediatric intestinal transplantation patients. Transplant Proc. 2006;38:1768–9.PubMedCrossRefGoogle Scholar
  143. 143.
    Serre J-E, Michonneau D, Bachy E, Noël L-H, Dubois V, Suberbielle C, Kreis H, Legendre C, Mamzer-Bruneel M-F, Morelon E. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney Int. 2014;85:182–90.PubMedCrossRefGoogle Scholar
  144. 144.
    Shpilberg O, Wilson J, Whiteside TL, Herberman RB. Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leuk Lymphoma. 1999;36:109–21.PubMedCrossRefGoogle Scholar
  145. 145.
    Simard JF, Baecklund E, Kinch A, Brattstrom C, Ingvar A, Molin D, Adami J, Fernberg P, Wilczek H, Ekbom A, Smedby KE. Pediatric organ transplantation and risk of premalignant and malignant tumors in Sweden. Am J Transplant. 2011;11:146–51.PubMedCrossRefGoogle Scholar
  146. 146.
    Smith JM, Dharnidharka VR. Viral surveillance and subclinical viral infection in pediatric kidney transplantation. Pediatr Nephrol. 2015;30:741–8.PubMedCrossRefGoogle Scholar
  147. 147.
    Soriano-Lopez DP, Alcantar-Fierros JM, Hernandez-Plata JA, Gonzalez-Jorge AL, Velazquez-Ramos S, Flores-Hernandez MA, Fuentes V, Castaneda P, Nieto J, Sanchez JL, Lopez B, Valencia-Mayoral P, Varela-Fascinetto G. A scheduled program of molecular screening for Epstein-Barr virus decreases the incidence of post-transplantation lymphoproliferative disease in pediatric liver Transplantation. Transplant Proc. 2016;48:654–7.PubMedCrossRefGoogle Scholar
  148. 148.
    Stevens SJ, Stevens C, Verschuuren EAM, Pronk I, van der Bij W, Harmsen MC, Hauw The T, Meijer CJLM, van den Brule AJC, Middeldorp JM. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97:1165–71.PubMedCrossRefGoogle Scholar
  149. 149.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Blood Infectious Diseases Working Party of the European Group for, and Transplantation Marrow. Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the infectious diseases working Party of the European Group for blood and marrow Transplantation. Clin Infect Dis. 2013;57:794–802.PubMedCrossRefGoogle Scholar
  150. 150.
    Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, Ljungman P. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. haematologica. 2016;101:803–11.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Sun Q, Burton R, Reddy V. Safety of allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol. 2002;118:799–808.PubMedCrossRefGoogle Scholar
  152. 152.
    Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int. 2006;19:259–69.PubMedCrossRefGoogle Scholar
  153. 153.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Taylor E, Jones M, Hourigan MJ, Johnson DW, Gill DS, Isbel N, Hawley CM, Marlton P, Gandhi MK, Campbell SB. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Nephrol Dial Transplant. 2015;30:1774–9.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Tischer J, Engel N, Fritsch S, Prevalsek D, Hubmann M, Schulz C, Zoellner AK, Bucklein V, Reibke R, Mumm F, Rieger CT, Hill W, Ledderose G, Stemmler HJ, Kohnke T, Jager G, Kolb HJ, Schmid C, Moosmann A, Hausmann A. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol. 2015;94:1677–88.PubMedCrossRefPubMedCentralGoogle Scholar
  156. 156.
    Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dorken B, Oertel S. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation. 2007;83:912–8.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Duhrsen U, Reinke P, Verhoef G, Subklewe M, Huttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35:536–43.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13:196–206.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Trofe J, Buell JF, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG, Succop P, Woodle ES. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant. 2005;5:775–80.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    Tsai DE, Douglas L, Andreadis C, Vogl DT, Arnoldi S, Kotloff R, Svoboda J, Bloom RD, Olthoff KM, Brozena SC. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant. 2008;8:1016–24.PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, Winiarski J, Ljungman P, Remberger M, Mattsson J. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99:346–52.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Upton A, Diane H, Martin P, Raymond T, Dat T, Riccardo S, Derek S, Lori W, Samia W, Susan N. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clin Infect Dis. 2001;33:145–50.CrossRefGoogle Scholar
  163. 163.
    Vali R, Punnett A, Bajno L, Moineddin R, Shammas A. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis. Pediatr Transplant. 2015;19:932–9.PubMedCrossRefGoogle Scholar
  164. 164.
    van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer. 2008;50:886–8.PubMedCrossRefGoogle Scholar
  165. 165.
    Vase MØ, Maksten EF, Bendix K, Hamilton-Dutoit S, Andersen C, Møller MB, Sørensen SS, Jespersen B, Kampmann J, Søndergård E. Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. Leuk Lymphoma. 2015;56:1677–85.PubMedCrossRefGoogle Scholar
  166. 166.
    Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH, Barry J, Fraser N, Turner DM, Robertson V. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol. 2014;167:402–10.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979–81.PubMedCrossRefGoogle Scholar
  168. 168.
    Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, McGregor CG, Paya CV. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346–53.PubMedCrossRefGoogle Scholar
  169. 169.
    Webber S, Harmon W, Faro A, Green M, Sarwal M, Hayashi R, Canter C, Thomas D, Jaffe R, Fine R. Anti-CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid Organ Transplantation: multicenter experience from a registry and from a prospective Clinical trial. Blood. 2004;104:746.Google Scholar
  170. 170.
    Webber SA, Naftel DC, Jay Fricker F, Olesnevich P, Blume ED, Addonizio L, Kirklin JK, Canter CE. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367:233–9.CrossRefGoogle Scholar
  171. 171.
    Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005;4(4):CD003961.Google Scholar
  172. 172.
    Weintraub L, Weiner C, Miloh T, Tomaino J, Joashi U, Benchimol C, Strauchen J, Roth M, Wistinghausen B. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia. J Pediatr Hematol Oncol. 2014;36:e481–6.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Wiesmayr S, Webber SA, Macedo C, Popescu I, Smith L, Luce J, Metes D. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur J Immunol. 2012;42:541–50.PubMedCrossRefPubMedCentralGoogle Scholar
  174. 174.
    Wilkie GM, Taylor C, Jones MM, Burns DM, Turner M, Kilpatrick D, Amlot PL, Crawford DH, Haque T. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases. J Immunother. 2004;27:309–16.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Wu M, Huang F, Jiang X, Fan Z, Zhou H, Liu C, Jiang Q, Zhang Y, Zhao K, Xuan L, Zhai X, Zhang F, Yin C, Sun J, Feng R, Liu Q. Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. PLoS One. 2013;8:e77805.PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, Chen YH, Wang Y, Yan CH, Wang JZ, Wang FR, Zhao T, Liu YR, Liu KY, Huang XJ. Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant. 2015;21:2185–91.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Yamamoto N, Nishimura N, Takeuchi M, Ito T, Yokozaki H, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A. The emergence of CD20−/CD19− tumor cells after rituximab therapy for Epstein–Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2014;173:1615–8.PubMedCrossRefPubMedCentralGoogle Scholar
  178. 178.
    Yanik EL, Shiels MS, Smith JM, Clarke CA, Lynch CF, Kahn AR, Koch L, Pawlish KS, Engels EA. Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States. Cancer. 2017;123:4663–71.PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Zimmermann T, Hoppe-Lotichius M, Tripkovic V, Barreiros AP, Wehler TC, Zimmermann A, Schattenberg JM, Heise M, Biesterfeld S, Galle PR, Otto G, Schuchmann M. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). Eur J Intern Med. 2010;21:208–15.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ashley V. Geerlinks
    • 1
  • Thomas G. Gross
    • 2
  • Angela S. Punnett
    • 1
    Email author
  1. 1.Division of Haematology/OncologyHospital for Sick Children, University of TorontoTorontoCanada
  2. 2.Center for Global Health, NCI, NIH, DHHSRockvilleUSA

Personalised recommendations